Filter By:

Binimetinib

11/07/2016

2016 Society for Melanoma Research (SMR) Annual Congress

Efficacy of Binimetinib in Patients with NRAS-mutant Melanoma: Subgroup Analysis of the Phase 3 NEMO Study

A. Arance, et al.

ARRY-797

08/31/2016

European Society of Cardiology Congress 2016

Phase 2 Study of A797, an Oral, Selective p38 Mitogen-Activated Protein Kinase Inhibitor, in Patients With Lamin A/C–Related Dilated Cardiomyopathy

C. A. MacRae, et al.

Filanesib

07/19/2016

PubMed.gov

A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma.

Chari A., et al.

Encorafenib

07/01/2016

ESMO World Congress of Gastrointestinal Cancer

Combination of Encorafenib and Cetuximab With or Without Alpelisib in Patients With Advanced BRAF-Mutant (BRAFm) Colorectal Cancer: Phase 2 Results

J. Tabernero, et al.

Binimetinib

06/06/2016

American Society of Clinical Oncology Meeting

Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma

R. Dummer, et al.

Encorafenib

06/01/2016

American Society of Clinical Oncology Meeting

Phase 2 results: encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC)

J. Tabernero, et al.

Filanesib

12/07/2015

American Society of Hematology Annual Meeting 2015

Phase 2 Study of Carfilzomib With or Without Filanesib in Patients With Advanced Multiple Myeloma (MM)

J. Zonder, et al.

Filanesib

12/05/2015

American Society of Hematology Annual Meeting 2015

Mechanisms Underlying the Synergistic Interaction of Filanesib with Pomalidomide and Dexamethasone (FPD) in Multiple Myeloma

S. Hernandez-Garcia, et al.

Binimetinib

09/28/2015

European Cancer Congress

A Phase 1b/2 Study of Ribociclib (LEE011; CDK4/6 inhibitor) in Combination With Binimetinib (MEK162; MEK inhibitor) in Patients With NRAS‐Mutant Melanoma

C. van Herpen, et al.

Binimetinib

09/27/2015

European Cancer Congress

LOGIC2: Phase 2, Multi-center, Open-label Study of Sequential Encorafenib/Binimetinib Combination Followed by a Rational Combination with Targeted Agents After Progression, to Overcome Resistance in Adult Patients with Locally Advanced or Metastatic BRAF V600 Melanoma

R. Dummer, et al.